Rheumatoid Arthritis
Conditions
Brief summary
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with moderate to severe rheumatoid arthritis. Data will be collected from each eligible participant initiated on RoActemra/Actemra treatment by their treating physician according to local label for 6 months from start of treatment.
Interventions
DRUGTocilizumab
Participants received tocilizumab according to individualized physician-prescribed regimens.
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult participants, \>/= 18 years of age * Moderate to severe rheumatoid arthritis * Participants initiating treatment with RoActemra/Actemra on their physician's decision (in accordance with the local label), including participants who started treatment with RoActemra/Actemra in the 8 weeks prior to the enrolment visit
Exclusion criteria
* RoActemra/Actemra treatment more than 8 weeks prior to the enrolment visit * Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use * Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra * History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation | 6 months after treatment initiation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Stopped Disease-Modifying Antirheumatic Drugs (DMARDs) Prior to Start of Tocilizumab | Baseline | — |
| Percentage of Participants Who Previously Received DMARDs | Baseline | — |
| Reason for DMARDs Withdrawal at Baseline | Baseline | — |
| Number of Participants Who Stopped Biologic Agents Prior to Start of Tocilizumab | Baseline | — |
| Percentage of Participants Who Previously Received Biologic Agents | Baseline | — |
| Reason for Biologic Agent Withdrawal at Baseline | Baseline | — |
| Reasons for Dose Modifications | approximately 3 years | — |
| Percentage of Participants Who Discontinued From Tocilizumab for Safety Versus Efficacy | Approximately 3 years | — |
| Percentage of Participants on Tocilizumab as Monotherapy or Combination Therapy | Baseline, Month 6 | Percentage of participants on Tocilizumab as monotherapy or combination therapy (with DMARDs) were reported at start of treatment and at 6 months from the start of treatment. |
| Change From Baseline in Tender Joint Count (TJC) at Month 3 and Month 6 | Baseline, Month 3, Month 6 | The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 28 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A decrease in score indicated improvement. |
| Change From Baseline in Swollen Joint Count (SJC) at Month 3 and Month 6 | Baseline, Month 3, Month 6 | The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1, for 28 joints and were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A decrease in score indicates improvement. |
| Percentage of Participants With Systemic Manifestations of RA at Baseline | Baseline | Systemic manifestations of RA included anemia, fatigue, conventional risk factors for cardiovascular disease, C-Reactive Protein (CRP) above upper limit of normal, rheumatoid nodules, rheumatoid vasculitis and interstitial lung disease. Participants were included if they experienced at least one of the conditions. |
| Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | Month 3, Month 6 | CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGH and physician global assessment of disease activity (PhGH) assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity. |
| Simplified Disease Activity (SDAI) Response Classification | Month 3, Month 6 | The SDAI was a combined index for measuring disease activity in RA which reflected the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PGH and PhGH, assessed on 0-100 mm VAS where 0 = no disease activity and 100 = worst disease activity, and C-reactive protein (CRP). SDAI total score = 0-86. A SDAI score \</= 3.3 represented clinical remission, a score of between 3.4 and 11.0 represented low disease activity, a score between 11 and 26.0 represented moderate disease activity and a score \> 26.0 represented high (or severe) disease. |
| European League Against Rheumatism (EULAR) Response | Month 3, Month 6 | Clinical response assessed as per EULAR categorical DAS28 response criteria was defined as clinically meaningful improvement at a particular time point. EULAR response was based on change from baseline (CFB) in the DAS28 score and also on the actual DAS28 score at the time point so was more reflective of the current status of the participant. The DAS28 score was a measure of the participant's disease activity, based on the TJC (28 joints), SJC (28 joints), PGH, and ESR. DAS28 total scores ranged from 0 to approximately 10. Scores \<2.6 = best disease control and scores \>5.1 = worse disease control. A negative CFB indicated clinically meaningful improvement. EULAR Good response: DAS28 \<=3.2 and a CFB \<-1.2. EULAR Moderate response: DAS28 \>3.2 to ≤ 5.1 or a CFB \< -0.6 to ≥ -1.2. EULAR No response: DAS28 ≤3.2 or CFB greater than or equal to (\>=) -0.6, DAS28 \>3.2 to \<=5.1 or CFB\>=-0.6 and DAS28 \>5.1 or CFB \>=-0.6. |
| Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | Month 3, Month 6 | ACR response was calculated based on total joint count evaluation (28 or 66/68 joint count) and other clinical and laboratory assessments. A positive ACR20 response required at least a 20% improvement (reduction) compared to baseline in swollen joint count (66 joints) and tender joint count (68 joints) and at least 3 of the following 5 assessments: patient's global assessment of pain, PGH, PhGH (all 3 assessed at 0 \[good\] to 100 mm \[worst\] VAS scale), participant assessment of disability measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessed on a 0 to 3 scale, where higher scores represented higher disease activity), Acute phase reactant (CRP or ESR). A reduction in the level of and acute phase reactants was considered an improvement. ACR50, ACR70, ACR90 require a 50%, 70%, 90% improvement from baseline respectively. |
| Change From Baseline in Physician Global Assessment of Disease Activity at Month 3 and Month 6 | Baseline, Month 3, Month 6 | The physician's global assessment of disease activity was assessed using a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as no disease activity (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as maximum disease activity (maximum arthritis disease activity). A negative change from Baseline indicated improvement. |
| Change From Baseline in Patient's Global Assessment of Disease Activity at Month 3 and Month 6 | Baseline, Month 3, Month 6 | The Patient Global Assessment of disease activity provides an overall assessment of how RA affects the participant using a visual analogue score, where 0 indicates they are managing very well and 100 indicates they are managing very poorly. A decrease in the score indicates improvement. |
| Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | Baseline, Month 3, Month 6 | The HAQ-DI was a participant self-reported questionnaire for assessing the extent of a participant's functional ability. It consisted of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question had 4 response options, ranging from 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The HAQ-DI scale was an average of all the scores and ranged from 0 to 3, where higher scores represented higher disease activity. |
| Change From Baseline in Patient's Global Assessment of Fatigue at Month 3 and Month 6 | Baseline, Month 3, Month 6 | The Patient Global Assessment of fatigue provides an overall assessment of the level of fatigue that the participant is experiencing using a visual analogue score, where 0 indicates no fatigue and 100 indicates extreme fatigue. A decrease in the score indicates improvement. |
| Change From Baseline in Patient's Global Assessment of Pain at Month 3 and Month 6 | Baseline, Month 3, Month 6 | The Patient Global Assessment of pain provides an overall assessment of the severity of pain that the participant is experiencing using a visual analogue score, where 0 indicates no pain and 100 indicates unbearable pain. A decrease in the score indicates improvement. |
| Change From Baseline in Patient's Severity of Morning Stiffness at Month 3 and Month 6 | Baseline, Month 3, Month 6 | Morning stiffness was defined by the time elapsed between the time of usual awakening (even if not in the morning) and the time the participant was as limber as he/she would be during a day involving typical activities. Morning stiffness was assessed on a 100 mm VAS, where 0= none and 100= very severe. |
| Percentage of Participants With an Adverse Event (AE) | approximately 3 years | An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. |
| Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | Month 3, Month 6 | DAS28 was calculated from SJC and TJC using 28 joints count, erythrocyte sedimentation rate (ESR) (millimeter per hour \[mm/hr\]), and patient global assessment of disease activity (PGH) (measured on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS) where 0=no disease activity and 100=worst disease activity). DAS28 is a measurement of RA activity on a 0 to 10 scale: a score greater than (\>) 5.1 indicates high disease activity; a score between 3.2 and 5.1 indicates moderate disease activity; a score of less than 3.2 indicates low disease activity; a score of less than (\<) 2.6 is considered remission. |
Countries
Argentina
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tocilizumab Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens. | 50 |
| Total | 50 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 2 |
| Overall Study | Infusion not received at 6 month window | 4 |
| Overall Study | Lack of Efficacy | 1 |
| Overall Study | Participant drop-out | 1 |
Baseline characteristics
| Characteristic | Tocilizumab |
|---|---|
| Age, Continuous | 53.9 years STANDARD_DEVIATION 12.2 |
| Sex: Female, Male Female | 41 Participants |
| Sex: Female, Male Male | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 50 |
| serious Total, serious adverse events | 2 / 50 |
Outcome results
Primary
Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation
Time frame: 6 months after treatment initiation
Population: The Full Analysis Set (FAS) was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation | 84 percentage of participants |
Secondary
Change From Baseline in Patient's Global Assessment of Disease Activity at Month 3 and Month 6
The Patient Global Assessment of disease activity provides an overall assessment of how RA affects the participant using a visual analogue score, where 0 indicates they are managing very well and 100 indicates they are managing very poorly. A decrease in the score indicates improvement.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measurement at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity at Month 3 and Month 6 | Baseline (n=39) | 65 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity at Month 3 and Month 6 | Change at Month 3 (n=31) | -10 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Disease Activity at Month 3 and Month 6 | Change at Month 6 (n=30) | -15 units on a scale |
Secondary
Change From Baseline in Patient's Global Assessment of Fatigue at Month 3 and Month 6
The Patient Global Assessment of fatigue provides an overall assessment of the level of fatigue that the participant is experiencing using a visual analogue score, where 0 indicates no fatigue and 100 indicates extreme fatigue. A decrease in the score indicates improvement.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measurement at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Fatigue at Month 3 and Month 6 | Baseline (n=28) | 70 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Fatigue at Month 3 and Month 6 | Change at Month 3 (n=23) | -35 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Fatigue at Month 3 and Month 6 | Change at Month 6 (n=22) | -30 units on a scale |
Secondary
Change From Baseline in Patient's Global Assessment of Pain at Month 3 and Month 6
The Patient Global Assessment of pain provides an overall assessment of the severity of pain that the participant is experiencing using a visual analogue score, where 0 indicates no pain and 100 indicates unbearable pain. A decrease in the score indicates improvement.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measurement at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Pain at Month 3 and Month 6 | Baseline (n=37) | 80 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Pain at Month 3 and Month 6 | Change at Month 3 (n=30) | -23 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Global Assessment of Pain at Month 3 and Month 6 | Change at Month 6 (n=29) | -25 units on a scale |
Secondary
Change From Baseline in Patient's Severity of Morning Stiffness at Month 3 and Month 6
Morning stiffness was defined by the time elapsed between the time of usual awakening (even if not in the morning) and the time the participant was as limber as he/she would be during a day involving typical activities. Morning stiffness was assessed on a 100 mm VAS, where 0= none and 100= very severe.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measurement at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Patient's Severity of Morning Stiffness at Month 3 and Month 6 | Baseline (n=21) | 60 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Severity of Morning Stiffness at Month 3 and Month 6 | Change at Month 3 (n=16) | -50 units on a scale |
| Tocilizumab | Change From Baseline in Patient's Severity of Morning Stiffness at Month 3 and Month 6 | Change at Month 6 (n=14) | -25 units on a scale |
Secondary
Change From Baseline in Physician Global Assessment of Disease Activity at Month 3 and Month 6
The physician's global assessment of disease activity was assessed using a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as no disease activity (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as maximum disease activity (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measurement at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Physician Global Assessment of Disease Activity at Month 3 and Month 6 | Baseline (n=35) | 51 units on a scale |
| Tocilizumab | Change From Baseline in Physician Global Assessment of Disease Activity at Month 3 and Month 6 | Change at Month 3 (n=29) | -10 units on a scale |
| Tocilizumab | Change From Baseline in Physician Global Assessment of Disease Activity at Month 3 and Month 6 | Change at Month 6 (n=27) | -20 units on a scale |
Secondary
Change From Baseline in Swollen Joint Count (SJC) at Month 3 and Month 6
The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1, for 28 joints and were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A decrease in score indicates improvement.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measure at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Swollen Joint Count (SJC) at Month 3 and Month 6 | Baseline (n=29) | 8 units on a scale |
| Tocilizumab | Change From Baseline in Swollen Joint Count (SJC) at Month 3 and Month 6 | Change at Month 3 (n=22) | -5 units on a scale |
| Tocilizumab | Change From Baseline in Swollen Joint Count (SJC) at Month 3 and Month 6 | Change at Month 6 (n=22) | -7.50 units on a scale |
Secondary
Change From Baseline in Tender Joint Count (TJC) at Month 3 and Month 6
The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 28 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A decrease in score indicated improvement.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measure at the specified time point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tocilizumab | Change From Baseline in Tender Joint Count (TJC) at Month 3 and Month 6 | Baseline (n=29) | 12 units on a scale |
| Tocilizumab | Change From Baseline in Tender Joint Count (TJC) at Month 3 and Month 6 | Change at Month 3 (n=22) | -6 units on a scale |
| Tocilizumab | Change From Baseline in Tender Joint Count (TJC) at Month 3 and Month 6 | Change at Month 6 (n=22) | -9 units on a scale |
Secondary
Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6
CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGH and physician global assessment of disease activity (PhGH) assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.
Time frame: Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Number of participants analyzed signifies the participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | <= 2.8 Clinical remission at Month 3 | 1 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | <= 2.8 Clinical remission at Month 6 | 2 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | > 2.8 and <= 10.0 Low disease activity at Month 3 | 7 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | > 2.8 and <= 10.0 Low disease activity at Month 6 | 7 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | > 10.0 and <= 22.0 Moderate activity at Month 3 | 6 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | > 10.0 and <= 22.0 Moderate activity at Month 6 | 9 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | > 22.0 High disease activity at Month 3 | 9 participants |
| Tocilizumab | Clinical Disease Activity Index (CDAI) Response Classification at Month 3 and Month 6 | > 22.0 High disease activity at Month 6 | 5 participants |
Secondary
Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6
DAS28 was calculated from SJC and TJC using 28 joints count, erythrocyte sedimentation rate (ESR) (millimeter per hour \[mm/hr\]), and patient global assessment of disease activity (PGH) (measured on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS) where 0=no disease activity and 100=worst disease activity). DAS28 is a measurement of RA activity on a 0 to 10 scale: a score greater than (\>) 5.1 indicates high disease activity; a score between 3.2 and 5.1 indicates moderate disease activity; a score of less than 3.2 indicates low disease activity; a score of less than (\<) 2.6 is considered remission.
Time frame: Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Number of participants analyzed signifies the participants who were evaluable for this outcome measure. Here, 'n' represents the number of participants with a measure at the specified time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | < 2.6 Clinical Remission at Month 3 (n=2) | 0 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | <2.6 Clinical Remission at Month 6 (n=4) | 0 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | >=2.6-<=3.2 Low Disease Activity at Month 3 (n=2) | 0 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | >=2.6-<=3.2 Low Disease Activity at Month 6 (n=4) | 3 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | >3.2-<=5.1 Moderate Disease at Month 3(n=2) | 2 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | >3.2-<=5.1 Moderate Disease at Month 6 (n=4) | 1 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | >5.1 High Disease Activity at Month 3 (n=2) | 0 participants |
| Tocilizumab | Disease Activity Score-28 (DAS 28) Response Classification at Month 3 and Moth 6 | >5.1 High Disease Activity at Month 6 (n=4) | 0 participants |
Secondary
European League Against Rheumatism (EULAR) Response
Clinical response assessed as per EULAR categorical DAS28 response criteria was defined as clinically meaningful improvement at a particular time point. EULAR response was based on change from baseline (CFB) in the DAS28 score and also on the actual DAS28 score at the time point so was more reflective of the current status of the participant. The DAS28 score was a measure of the participant's disease activity, based on the TJC (28 joints), SJC (28 joints), PGH, and ESR. DAS28 total scores ranged from 0 to approximately 10. Scores \<2.6 = best disease control and scores \>5.1 = worse disease control. A negative CFB indicated clinically meaningful improvement. EULAR Good response: DAS28 \<=3.2 and a CFB \<-1.2. EULAR Moderate response: DAS28 \>3.2 to ≤ 5.1 or a CFB \< -0.6 to ≥ -1.2. EULAR No response: DAS28 ≤3.2 or CFB greater than or equal to (\>=) -0.6, DAS28 \>3.2 to \<=5.1 or CFB\>=-0.6 and DAS28 \>5.1 or CFB \>=-0.6.
Time frame: Month 3, Month 6
Population: Data was not collected, hence not reported.
Secondary
Number of Participants Who Stopped Biologic Agents Prior to Start of Tocilizumab
Time frame: Baseline
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Number of Participants Who Stopped Biologic Agents Prior to Start of Tocilizumab | 19 participants |
Secondary
Number of Participants Who Stopped Disease-Modifying Antirheumatic Drugs (DMARDs) Prior to Start of Tocilizumab
Time frame: Baseline
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Number of Participants Who Stopped Disease-Modifying Antirheumatic Drugs (DMARDs) Prior to Start of Tocilizumab | 5 participants |
Secondary
Percentage of Participants on Tocilizumab as Monotherapy or Combination Therapy
Percentage of participants on Tocilizumab as monotherapy or combination therapy (with DMARDs) were reported at start of treatment and at 6 months from the start of treatment.
Time frame: Baseline, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants on Tocilizumab as Monotherapy or Combination Therapy | Monotherapy at baseline | 14 percentage of participants |
| Tocilizumab | Percentage of Participants on Tocilizumab as Monotherapy or Combination Therapy | With DMARDs at baseline | 86 percentage of participants |
| Tocilizumab | Percentage of Participants on Tocilizumab as Monotherapy or Combination Therapy | Monotherapy at Month 6 | 14 percentage of participants |
| Tocilizumab | Percentage of Participants on Tocilizumab as Monotherapy or Combination Therapy | With DMARDs at Month 6 | 86 percentage of participants |
Secondary
Percentage of Participants Who Discontinued From Tocilizumab for Safety Versus Efficacy
Time frame: Approximately 3 years
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Who Discontinued From Tocilizumab for Safety Versus Efficacy | Adverse Event | 4 percentage of participants |
| Tocilizumab | Percentage of Participants Who Discontinued From Tocilizumab for Safety Versus Efficacy | Lack of Efficacy | 2 percentage of participants |
Secondary
Percentage of Participants Who Previously Received Biologic Agents
Time frame: Baseline
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Who Previously Received Biologic Agents | 0 Biologic Agents | 62.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received Biologic Agents | 1 Biologic Agent | 16.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received Biologic Agents | 2 Biologic Agents | 16.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received Biologic Agents | 3 Biologic Agents | 4.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received Biologic Agents | 4 Biologic Agents | 2.00 percentage of participants |
Secondary
Percentage of Participants Who Previously Received DMARDs
Time frame: Baseline
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 0 DMARDs | 48.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 1 DMARD | 24.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 2 DMARDs | 14.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 3 DMARDs | 10.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 4 DMARDs | 0.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 5 DMARDs | 1 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 6 DMARDs | 2.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 7 DMARDs | 0.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 8 DMARDs | 0.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 9 DMARDs | 0.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 10 DMARDs | 0.00 percentage of participants |
| Tocilizumab | Percentage of Participants Who Previously Received DMARDs | 11 DMARDs | 2.00 percentage of participants |
Secondary
Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6
ACR response was calculated based on total joint count evaluation (28 or 66/68 joint count) and other clinical and laboratory assessments. A positive ACR20 response required at least a 20% improvement (reduction) compared to baseline in swollen joint count (66 joints) and tender joint count (68 joints) and at least 3 of the following 5 assessments: patient's global assessment of pain, PGH, PhGH (all 3 assessed at 0 \[good\] to 100 mm \[worst\] VAS scale), participant assessment of disability measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessed on a 0 to 3 scale, where higher scores represented higher disease activity), Acute phase reactant (CRP or ESR). A reduction in the level of and acute phase reactants was considered an improvement. ACR50, ACR70, ACR90 require a 50%, 70%, 90% improvement from baseline respectively.
Time frame: Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Number of participants analyzed signifies the participants who were evaluable for this outcome measure. Here, 'n' represents the number of participants with a measure at the specified time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 20 at Month 3 (n=21) | 38.10 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 20 at Month 6 (n=22) | 68.18 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 50 at Month 3 (n=21) | 23.81 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 50 at Month 6 (n=22) | 40.91 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 70 at Month 3 (n=21) | 14.29 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 70 at Month 6 (n=22) | 13.64 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 90 at Month 3 (n=21) | 0.00 percentage of participants |
| Tocilizumab | Percentage of Participants With American College of Rheumatology (ACR) Response at Month 3 and Month 6 | ACR 90 at Month 6 (n=22) | 9.09 percentage of participants |
Secondary
Percentage of Participants With an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug.
Time frame: approximately 3 years
Population: Safety population was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Percentage of Participants With an Adverse Event (AE) | 56.00 percentage of participants |
Secondary
Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI)
The HAQ-DI was a participant self-reported questionnaire for assessing the extent of a participant's functional ability. It consisted of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question had 4 response options, ranging from 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The HAQ-DI scale was an average of all the scores and ranged from 0 to 3, where higher scores represented higher disease activity.
Time frame: Baseline, Month 3, Month 6
Population: FAS was defined as all participants who received at least one dose of Tocilizumab. Here, 'n' represents the number of participants with a measure at the specified time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | < 0.5 Clinical Remission at Baseline (n=33) | 6.06 percentage of participants |
| Tocilizumab | Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | >= 0.5 No remission at Baseline (n=33) | 93.94 percentage of participants |
| Tocilizumab | Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | < 0.5 Clinical Remission at Month 3 (n=25) | 40.00 percentage of participants |
| Tocilizumab | Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | >= 0.5 No remission at Month 3 (n=25) | 60.00 percentage of participants |
| Tocilizumab | Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | < 0.5 Clinical Remission at Month 6 (n=26) | 26.92 percentage of participants |
| Tocilizumab | Percentage of Participants With Clinical Remission in Health Assessment Questionnaire Disability Index (HAQ-DI) | >= 0.5 No remission at Month 6 (n=26) | 73.08 percentage of participants |
Secondary
Percentage of Participants With Systemic Manifestations of RA at Baseline
Systemic manifestations of RA included anemia, fatigue, conventional risk factors for cardiovascular disease, C-Reactive Protein (CRP) above upper limit of normal, rheumatoid nodules, rheumatoid vasculitis and interstitial lung disease. Participants were included if they experienced at least one of the conditions.
Time frame: Baseline
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tocilizumab | Percentage of Participants With Systemic Manifestations of RA at Baseline | 40 percentage of participants |
Secondary
Reason for Biologic Agent Withdrawal at Baseline
Time frame: Baseline
Population: FAS defined as all participants who received at least one dose of Tocilizumab. Number of participants analyzed signifies the participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Reason for Biologic Agent Withdrawal at Baseline | Lack of efficacy | 13 participants |
| Tocilizumab | Reason for Biologic Agent Withdrawal at Baseline | Adverse event | 1 participants |
| Tocilizumab | Reason for Biologic Agent Withdrawal at Baseline | Other - reason not specified | 2 participants |
| Tocilizumab | Reason for Biologic Agent Withdrawal at Baseline | Unknown | 3 participants |
Secondary
Reason for DMARDs Withdrawal at Baseline
Time frame: Baseline
Population: FAS defined as all participants who received at least one dose of Tocilizumab. Number of participants analyzed signifies the participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Reason for DMARDs Withdrawal at Baseline | Adverse event | 2 participants |
| Tocilizumab | Reason for DMARDs Withdrawal at Baseline | Unknown | 2 participants |
| Tocilizumab | Reason for DMARDs Withdrawal at Baseline | Other - reason not specified | 1 participants |
Secondary
Reasons for Dose Modifications
Time frame: approximately 3 years
Population: FAS was defined as all participants who received at least one dose of Tocilizumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tocilizumab | Reasons for Dose Modifications | Adverse Event | 1 participants |
| Tocilizumab | Reasons for Dose Modifications | Other | 21 participants |
Secondary
Simplified Disease Activity (SDAI) Response Classification
The SDAI was a combined index for measuring disease activity in RA which reflected the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PGH and PhGH, assessed on 0-100 mm VAS where 0 = no disease activity and 100 = worst disease activity, and C-reactive protein (CRP). SDAI total score = 0-86. A SDAI score \</= 3.3 represented clinical remission, a score of between 3.4 and 11.0 represented low disease activity, a score between 11 and 26.0 represented moderate disease activity and a score \> 26.0 represented high (or severe) disease.
Time frame: Month 3, Month 6
Population: Data was not collected, hence not reported.